Advertisement
Screener

Royalty Pharma plc (RPRX) Transfer from Investments

Royalty Pharma plc Transfer from Investments

Royalty Pharma plc (RPRX) reported Transfer from Investments of $0 for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.

Discontinued › Cash Flow

us-gaap:TransferOfInvestments · last filed 2021-11-10

  • Royalty Pharma plc transfer from investments for the quarter ending 2021-09-30 was $0.00.
  • Royalty Pharma plc transfer from investments for the quarter ending 2021-06-30 was $0.00.
  • Royalty Pharma plc transfer from investments for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
  • Royalty Pharma plc transfer from investments for the quarter ending 2020-12-31 was $297.98M.
  • Royalty Pharma plc transfer from investments for fiscal 2020 was $303.68M.
  • Royalty Pharma plc transfer from investments for fiscal 2019 was $0.00.
  • Royalty Pharma plc transfer from investments for fiscal 2018 was $0.00.
Period endTransfer from Investments 3 monthTransfer from Investments 6 monthTransfer from Investments 9 monthTransfer from Investments 9 month as first filedTransfer from Investments 12 month
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
$0.00
derived: sum of 2 quarters · filed 2021-11-10
$0.00
10-Q · filed 2021-11-10
$297.98M
derived: sum of 4 quarters · filed 2021-11-10
2021-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11
$0.00
10-Q · filed 2021-08-11
$297.98M
derived: sum of 3 quarters · filed 2021-08-11
$0.00
derived: sum of 4 quarters · filed 2021-11-10
2021-03-31$0.00
10-Q · filed 2021-05-11
$297.98M
derived: sum of 2 quarters · filed 2021-05-11
$0.00
derived: sum of 3 quarters · filed 2021-11-10
$0.00
derived: sum of 4 quarters · filed 2021-11-10
2020-12-31$297.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
$0.00
derived: sum of 2 quarters · filed 2021-11-10
$0.00
derived: sum of 3 quarters · filed 2021-11-10
$303.68M
10-K · filed 2021-02-24
2020-09-30-$297.98M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
-$297.98M
derived: sum of 2 quarters · filed 2021-11-10
$5.70M
10-Q · filed 2021-11-10
$303.68M
10-Q · filed 2020-11-12
$5.70M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11
$303.68M
10-Q · filed 2021-08-11
$303.68M
derived: sum of 3 quarters · filed 2021-08-11
$303.68M
derived: sum of 4 quarters · filed 2021-08-11
2020-03-31$303.68M
10-Q · filed 2021-05-11
$303.68M
derived: sum of 2 quarters · filed 2021-05-11
$303.68M
derived: sum of 3 quarters · filed 2021-05-11
2019-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
$0.00
derived: sum of 2 quarters · filed 2021-02-24
$0.00
10-K · filed 2021-02-24
2019-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12
$0.00
10-Q · filed 2020-11-12
2019-06-30$0.00
10-Q · filed 2020-08-12
2018-12-31$0.00
10-K · filed 2021-02-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
INSMED Inc (INSM)United States$26.566B-26.60
Zoetis Inc. (ZTS)United States$29.045B11.38
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80